Legal & General Group
PRDS

Legal & General Group’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Legal & General Group’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,966
Closed -$5.28K – 3576
2023
Q1 		$5.28K Hold
3,966
– – ﹤0.01% 3297
2022
Q4 		$6.72K Hold
3,966
– – ﹤0.01% 3325
2022
Q3 		$7K Sell
3,966
-804
-17% -$2.4K ﹤0.01% 3385
2022
Q2 		$15K Buy
+4,770
New +$29.1K ﹤0.01% 3318

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Legal & General Group's PRDS Position: Q2 2023 in Review

Legal & General Group sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 3,966 shares — an estimated $5.28K sold.

Legal & General Group first reported a position in PRDS in Q2 2022 and held it in 4 quarters. The position peaked at $15K in Q2 2022. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

  • Legal & General Group reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 3,966 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.28K.
  • Legal & General Group first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Legal & General Group's Pardes Biosciences, Inc. Common Stock position peaked at $15K in Q2 2022.
  • 59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.